You are going to see this everywhere over the next twelve months, and most of the coverage is going to be terrible. The formula is predictable. A beauty publication discovers a treatment that has been standard in Seoul for a decade. They interview a Manhattan derm who does not offer it. They describe it as “the buzzy new Korean skincare trend.” They mention that it involves salmon DNA. They include a floating aquarium visual. They say nothing about mechanism, regulatory status, or how any of it actually works.
The category deserves better than that, because the underlying science is genuinely interesting. Polydeoxyribonucleotide (PDRN) and polynucleotide (PN) injectables are one of the rare examples of a heavily marketed aesthetic treatment that turns out to have a well-characterized biological mechanism, decades of clinical use, and a peer-reviewed literature that mostly tracks with the manufacturer claims. They also happen to be entirely unregulated in the United States, which is the part almost no one is writing about.
Here is what is actually going on.
What PDRN and PN actually are
Both PDRN and PN are extracted from the sperm cells or roe of chum salmon (Oncorhynchus keta) — a species chosen because its DNA shares approximately 95% homology with human DNA, which means the fragments the human body receives are close enough to endogenous DNA to be handled by the same biochemical machinery without triggering a significant immune response. This is not a marketing story about “natural” ingredients. It is a genuine biocompatibility argument, and it is why the source species matters.
The difference between the two molecules is length, and length changes everything about how they behave in the skin. PDRN is a mixture of short DNA fragments, typically 50 to 1,500 base pairs long, produced by purification and controlled fragmentation of the raw DNA. PN (polynucleotides) are much longer polymers, extending up to roughly 1,500 kilodaltons in molecular weight — entire chains of nucleotides rather than short fragments. Both are double-stranded, both are highly purified (the specification typically requires greater than 95% purity with essentially no residual protein), and both have been shown to be biocompatible in extensive testing. But the biology they trigger is different.
Rejuran, the product name that has captured most of the American search volume, is a PN product — long-chain polynucleotides. Placentex Integro, the Italian pharmaceutical that has been approved for wound healing and tissue repair in Europe since 2007, is a PDRN product — short fragments. These are not interchangeable. Most consumer coverage lumps them together, which is a real problem when someone is deciding what to actually get injected into their face.
How PDRN works — the mechanism that most articles skip
PDRN’s primary mechanism is not the one you would guess. It is not that the fragments “repair” anything by acting as raw material for new DNA synthesis, though there is some of that happening in a background biochemical pathway. The primary mechanism is that the short DNA fragments serve as ligands for a specific receptor on the surface of skin cells: the adenosine A2A receptor.
Adenosine A2A receptors are G-protein-coupled receptors that, when activated, initiate a cascade of intracellular signaling with several downstream effects relevant to skin. They elevate cyclic AMP (cAMP), which suppresses the pro-inflammatory transcription factor NF-κB. They increase expression of vascular endothelial growth factor (VEGF), promoting angiogenesis in damaged tissue. They upregulate collagen types I and III in fibroblasts, and they downregulate matrix metalloproteinase-1 (MMP-1) — the enzyme that breaks collagen down. The net result is a fibroblast that is producing more structural protein and destroying less of it. Over weeks of consistent stimulation, this shows up as measurably improved dermal density.
The A2A receptor mechanism is why PDRN has anti-inflammatory effects in addition to biostimulation effects. Chronic inflammation is a major driver of extrinsic aging, and the A2A pathway is one of the endogenous brakes the body uses to shut inflammation down. Activating it with an exogenous ligand is unusual but plausible pharmacology, and it explains why PDRN has been studied not only for aesthetic indications but for wound healing, ischemic tissue repair, diabetic foot ulcers, and osteoarthritis.
There is also a secondary mechanism — the salvage pathway. The DNA fragments themselves can be broken down into individual nucleotides that get taken up by cells and used as raw material for new nucleic acid synthesis. This is metabolically significant in tissues that are actively regenerating (wound beds, damaged fibroblasts) and probably contributes to the collagen-boosting effect, but it is not the primary story. The receptor activation is.
How PN differs
PN — the longer-chain polynucleotides used in Rejuran and related products — work through a partially overlapping but distinctly different mechanism. Because the molecules are much larger, they cannot easily be taken up whole by cells. Instead, they behave in tissue as a physical scaffold: a three-dimensional matrix that holds water (extremely well — the water-binding capacity of PN is one of the reasons it produces immediate visible plumping), gives structural support to the injection site, and provides a slow-release depot as the polymer is gradually degraded by extracellular enzymes into shorter fragments.
Those shorter fragments then engage the same A2A receptor mechanism as PDRN. So PN essentially combines an immediate physical effect (scaffolding, hydration, tissue volumization) with a slower biological effect (staged release of A2A ligands as the polymer breaks down). This is why PN products tend to have a more visible immediate result than PDRN products — and why the biological effects take longer to develop, over the course of a multi-session treatment protocol.
The 2025 comparative review in Pharmaceutics that synthesized over 200 published studies on PN and PDRN concluded that both molecules are safe, both are effective for skin quality improvement, but the clinical use cases are distinct. PDRN is more established for wound healing, tissue repair, and inflammation-driven indications. PN is more established for aesthetic skin quality — the “skin booster” category, targeting fine lines, laxity, and dermal thickness. Neither is a filler in the traditional sense. Both work by stimulating the tissue itself to produce better collagen and hyaluronic acid, rather than by physically occupying volume.
The 40 years of European regulatory history
This is the part that will surprise most American readers. PDRN was not invented in Korea and it was not popularized by Instagram. It was developed by an Italian pharmaceutical company, Mastelli, in the 1970s. Placentex Integro — the branded PDRN drug — was approved by the Italian Ministry of Health in 2007, though clinical use predates that formal approval by more than two decades. It is currently approved as a prescription drug in Italy, Spain, and several other European jurisdictions, with indications for tissue repair, wound healing, and cutaneous rejuvenation. There are hundreds of clinical papers on it in the European literature.
Korea, which most Americans associate with the origin of the category, is actually a downstream adopter. Korean pharmaceutical companies picked up the PDRN platform in the 1990s, refined the manufacturing (Korea’s salmon aquaculture and pharmaceutical purification infrastructure made scaled production practical), and by the 2000s had become the dominant global manufacturer. Rejuran itself launched in Korea in 2014 as a PN “skin healer” injectable and became one of the most-used aesthetic products in Korean derm clinics through the 2010s.
So the treatment that is being covered in 2026 as a hot new trend has, in fact, been in continuous clinical use across Europe and East Asia for essentially the entire adult life of anyone currently reading this article. The 40 years of European use have produced a safety profile that most newer aesthetic categories cannot match. Adverse event data is limited to the expected injection-site reactions (redness, mild swelling), rare cases of granuloma formation with older PDRN formulations, and no signal for allergic reaction, infection, or long-term tissue damage. The molecule has a very clean safety chart, particularly for something that has been used as broadly as it has.
Why the U.S. has none of it
The FDA has not approved PDRN or PN as an injectable in the United States for any indication. Rejuran is not FDA-cleared. Placentex is not FDA-cleared. Every U.S. clinic offering these treatments is either (a) importing product on a personal-use or non-commercial basis, (b) sourcing through gray-market channels of variable provenance, (c) sending patients to Canada, Mexico, or Korea for treatment, or (d) operating outside the strict interpretation of the regulations and hoping the FDA does not choose to enforce.
The reasons for the U.S. regulatory gap are structural, not scientific. Injectable products face a much higher regulatory bar than topical cosmetics. Under FDA rules, a salmon-DNA injectable would need to be classified as either a biologic (requiring a full BLA), a medical device (unusual for a biological injectable), or a combination product. None of the major manufacturers — the Korean pharmaceutical companies that own most of the commercial rights — have run the full U.S. clinical trial program that would be required for BLA approval. It has not been commercially worthwhile, given the size of the U.S. medical aesthetics market relative to the trial cost.
Rejuran’s manufacturer, Pharma Research, has publicly indicated interest in eventually pursuing U.S. approval, but no active clinical trial for U.S. registration has been posted. Realistically, this means Americans who want the treatment either travel, use unregulated providers, or wait several more years for the first properly approved U.S. product to enter the market. None of the three is a great option.
The actual clinical evidence
Trials on PDRN and PN for aesthetic indications, taken together, produce a fairly consistent picture. Skin elasticity, hydration, and dermal density all improve measurably over a multi-session treatment course. Wound healing time in surgical or trauma contexts is reduced, with the strongest evidence coming from the wound-care literature (which is where PDRN has been used clinically for decades). Fine lines improve modestly. Skin texture and pore appearance improve. Post-inflammatory pigmentation resolves faster. Overall skin quality endpoints move in a direction that is easy to see in before/after photos and hard to fake in the standardized measurements.
What the literature does not support is the more aggressive marketing claims — that PDRN/PN can replace fillers, restore volume in areas of significant fat loss, or produce a “facelift” effect. These are biostimulators. They improve the quality of the tissue that is there. They do not create tissue where none exists. Consumers who understand this get realistic outcomes. Consumers who do not, get disappointment.
The typical protocol involves three to four treatment sessions spaced two to four weeks apart, followed by maintenance every six to twelve months. Each session involves microinjection of the product across the face using either a fine needle or a cannula, depending on the injector’s technique and the specific product being used. Total downtime is minimal — typically a day of small injection marks that fade quickly.
What to actually do with this information
For anyone considering PDRN or PN in 2026, the questions that matter are not about whether the molecule works. It does. The questions are about supply chain, provider training, and legal risk.
Where is the product actually coming from? The gray-market supply of Rejuran and similar products in the U.S. is not well controlled. Legitimate Korean-manufactured product should have full traceable documentation, batch numbers, and manufacturer authentication. Product that arrives in a plain box, or from a supplier the clinic cannot identify by name, is a red flag — not because salmon DNA is dangerous, but because unregulated supply chains have been the source of counterfeit product, contamination events, and mislabeled concentrations across aesthetic medicine.
Is the injector actually trained on it? The technique for skin-booster microinjection is different from filler injection technique. A provider who has done ten thousand Botox injections but is new to Rejuran is a provider who is learning on you. Ask specifically how many sessions of this exact product they have done, and where they trained.
Are you comfortable with the regulatory status? This is a personal calculation. The molecule is safe. The European safety data is robust. But the treatment is not FDA-approved for aesthetic use in the U.S., which means the standard consumer protections that come with an approved drug or device do not apply. If something goes wrong — even something minor — the recourse is limited. This is a real consideration even when the underlying molecule is well-characterized.
For most people, the realistic move is patience. The U.S. approval pathway for this class of molecule is going to open over the next three to five years as one of the major manufacturers finally commits to the trial program. When that happens, the treatment will become genuinely accessible under proper regulatory oversight. For the more risk-tolerant, medical tourism to Korea or Canada remains a real option and produces good outcomes when the provider is competent.
The bigger picture
PDRN and PN are a case study in how the U.S. medical aesthetics regulatory system fails at the specific task of getting well-characterized international treatments to American consumers in a timely way. The molecule works. The safety data exists. Two dozen countries have approved it. The FDA has not, because the pathway is expensive and the incentives for a Korean manufacturer to run the U.S. trial program have historically been weak. In the meantime, U.S. clinics offer it anyway, patients receive it anyway, and the regulatory gap is filled by improvisation.
The question is not whether Americans will end up with legal, regulated PDRN/PN injectables. They will. The question is how long the gap between international standard-of-care and U.S. availability stays open, and how many patients receive the treatment through unregulated channels in the meantime. The current answer is: several more years, and a lot.
The salmon DNA joke writes itself, and every publication in the category has written it. The actual story is more interesting: a 40-year-old European drug, a Korean commercial scale-up, a molecular class with a mapped receptor mechanism, and a U.S. regulatory system that has not caught up. The floating-aquarium framing is a distraction. The mechanism is not.